<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01543425</url>
  </required_header>
  <id_info>
    <org_study_id>CHU-0116</org_study_id>
    <nct_id>NCT01543425</nct_id>
  </id_info>
  <brief_title>Adrenocorticotropic Axis and Neuropathic Pain</brief_title>
  <acronym>HORMONES</acronym>
  <official_title>Status of the Hypothalamic-pituitary-gonado- Adrenal Axis (HHSG) in Patients With Neuropathic Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Clermont-Ferrand</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Clermont-Ferrand</source>
  <brief_summary>
    <textblock>
      Chronic pain is often associated with a chronic stress and HHSG axis plays a pivotal role in&#xD;
      maintaining homeostasis. The literature reports that pain in patients treated with opioids,&#xD;
      significant changes are taking place in this axis with a collapse in hormone concentrations&#xD;
      that are correlated with the decline on tests of quality of life and psychological testing.&#xD;
      The investigators hypothesis is that this &quot;endocrinopathy&quot; could also be present in patients&#xD;
      treated for neuropathic pain with other drug classes as opiates (antidepressants,&#xD;
      antiepileptics), and may explain, at least in part, the impairement of the quality of life of&#xD;
      these patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Day of inclusion: Blood sample for analysis of several hormones (cortisol, ACTH, SHBG, total&#xD;
      testostérone et S-DHEA, βœstradiol et progestérone for women, LH, FSH).&#xD;
&#xD;
      Day +1: salivary samples (at wake-up, 30 minutes after wake-up, at lunch, at 06:00 pm and&#xD;
      before sleep).&#xD;
&#xD;
      Day +2: salivary samples (at wake-up, 30 minutes after wake-up).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>hormonal status of neuropathic patients (blood sample )</measure>
    <time_frame>at day 0</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>hormonal status of neuropathic patients, salivary sample</measure>
    <time_frame>at day 1 and 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Collection of different drug classes (antidepressants, antiepileptics, opioids)</measure>
    <time_frame>at day 0,</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>scale anxiety / depression HAD</measure>
    <time_frame>at day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cognitive state</measure>
    <time_frame>at day 0,</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF36 questionnaire</measure>
    <time_frame>at day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>physical activity questionnaire (IPAQ)</measure>
    <time_frame>at day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>body mass index (BMI / Impedancemetry)</measure>
    <time_frame>at day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>waist circumference</measure>
    <time_frame>at day 0</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">120</enrollment>
  <condition>Neuropathic Pain</condition>
  <biospec_retention>None Retained</biospec_retention>
  <biospec_descr>
    <textblock>
      Day of inclusion: Blood sample for analysis of several hormones (cortisol, ACTH, SHBG, total&#xD;
      testostérone et S-DHEA, βœstradiol et progestérone for women, LH, FSH).&#xD;
&#xD;
      Day +1: salivary samples (at wake-up, 30 minutes after wake-up, at lunch, at 06:00 pm and&#xD;
      before sleep).&#xD;
&#xD;
      Day +2: salivary samples (at wake-up, 30 minutes after wake-up).&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients older than 18 years,&#xD;
&#xD;
          -  Male or Female with BMI between 18 and 35,&#xD;
&#xD;
          -  Patients with chronic neuropathic pain for more than six months, except to diabetes or&#xD;
             central neuropathic pain&#xD;
&#xD;
          -  Patients receiving systemic therapy for treating chronic neuropathic pain such as&#xD;
             antidepressants, anticonvulsants or opiates for at least 6 months.&#xD;
&#xD;
        Group of healthy volunteers&#xD;
&#xD;
          -  non-painful healthy volunteers matched by age, sex, BMI and menopausal status for&#xD;
             women,&#xD;
&#xD;
          -  Free of analgesics within 8 days before the test,&#xD;
&#xD;
          -  Aged over 18 years,&#xD;
&#xD;
          -  Male or Female,&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Group of patients&#xD;
&#xD;
          -  Patients older than 18 years,&#xD;
&#xD;
          -  Male or Female with BMI between 18 and 35,&#xD;
&#xD;
          -  Patients with chronic neuropathic pain for more than six months, except to diabetes or&#xD;
             central neuropathic pain&#xD;
&#xD;
          -  Patients receiving systemic therapy for treating chronic neuropathic pain such as&#xD;
             antidepressants, anticonvulsants or opiates for at least 6 months.&#xD;
&#xD;
        Group of healthy volunteers&#xD;
&#xD;
          -  non-painful healthy volunteers matched by age, sex, BMI and menopausal status for&#xD;
             women,&#xD;
&#xD;
          -  Free of analgesics within 8 days before the test,&#xD;
&#xD;
          -  Aged over 18 years,&#xD;
&#xD;
          -  Male or Female,&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with a medical history and / or surgical judged by the investigator or his&#xD;
             representative as being incompatible with the test&#xD;
&#xD;
          -  Patients treated only by topical treatment (lidocaine patch only for example)&#xD;
&#xD;
          -  Pateints receiving corticosteroid treatment at the time of enrollment, or who received&#xD;
             such treatment during the last 6 months (regardless of the dosage form and dosage),&#xD;
&#xD;
          -  Inflammatory and evolutive pathology requiring long term treatment,&#xD;
&#xD;
          -  Type 2 diabetes,&#xD;
&#xD;
          -  Postmenopausal women with replacement therapy,&#xD;
&#xD;
          -  Weight change of more than 5% within 3 months before the study,&#xD;
&#xD;
          -  BMI &lt;18 or&gt; 35,&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gisèle PICKERING</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Clermont-Ferrand</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <study_first_submitted>February 28, 2012</study_first_submitted>
  <study_first_submitted_qc>March 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2012</study_first_posted>
  <last_update_submitted>May 13, 2013</last_update_submitted>
  <last_update_submitted_qc>May 13, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 14, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neuropathic Pain</keyword>
  <keyword>Adenocorticotrophic axis</keyword>
  <keyword>Psychological state</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

